Insmed (INSM) PT Raised to $35 at Credit Suisse Following FDA Approval of Arikayce
Tweet Send to a Friend
Credit Suisse analyst Martin Auster raised the price target on Insmed (NASDAQ: INSM) to $35.00 (from $33.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
